Try our Advanced Search for more refined results

Expert Analysis

Upshot Of 'Skinny Label' Case May Go Beyond Pharma

By Jason Shull ( February 3, 2026, 6:29 PM EST) -- On Jan. 16, the U.S. Supreme Court agreed to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that sits at the intersection of patent law, U.S. Food and Drug Administration regulation, and generic drug competition. The court's decision to grant certiorari follows a 2024 ruling by the U.S. Court of Appeals for the Federal Circuit that revived Amarin's induced infringement claims and allowed the case to proceed past the pleading stage....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies